<DOC>
<DOCNO>EP-0656359</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Substituted 6,11-ethano-6,11-dihydrobenzo¬b quinolizinium salts and compositionsand methods of use thereof
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31435	A61K31435	A61P900	A61P910	A61P2500	A61P2500	A61P2528	C07D45500	C07D45503	C07D47100	C07D47118	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P9	A61P9	A61P25	A61P25	A61P25	C07D455	C07D455	C07D471	C07D471	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

salts of Formula, 

pharmaceutical compositions containing them, and methods for the 
treatment or prevention of neurodegenerative disorders or neurotoxic 

injuries utilizing them. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
STERLING WINTHROP INC
</APPLICANT-NAME>
<APPLICANT-NAME>
STERLING WINTHROP INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DEHAVEN-HUDKINS DIANA L C O ST
</INVENTOR-NAME>
<INVENTOR-NAME>
DORITY JOHN ALAN C O STERING W
</INVENTOR-NAME>
<INVENTOR-NAME>
EARLEY WILLIAM GEORGE C O STER
</INVENTOR-NAME>
<INVENTOR-NAME>
KUMAR VIRENDRA C O STERING WIN
</INVENTOR-NAME>
<INVENTOR-NAME>
MALLAMO JOHN PETER C O CEPHALO
</INVENTOR-NAME>
<INVENTOR-NAME>
MILLER MATTHEW STEVEN C O STER
</INVENTOR-NAME>
<INVENTOR-NAME>
SUBRAMANYAM CHAKRAPANI C O STE
</INVENTOR-NAME>
<INVENTOR-NAME>
DEHAVEN-HUDKINS, DIANA L, C/O STERING WINTHROP INC
</INVENTOR-NAME>
<INVENTOR-NAME>
DORITY, JOHN ALAN, C/O STERING WINTHROP INC
</INVENTOR-NAME>
<INVENTOR-NAME>
EARLEY, WILLIAM GEORGE, C/O STERING WINTHROP INC
</INVENTOR-NAME>
<INVENTOR-NAME>
KUMAR, VIRENDRA, C/O STERING WINTHROP INC
</INVENTOR-NAME>
<INVENTOR-NAME>
MALLAMO, JOHN PETER, C/O CEPHALON INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
MILLER, MATTHEW STEVEN, C/O STERING WINTHROP INC
</INVENTOR-NAME>
<INVENTOR-NAME>
SUBRAMANYAM, CHAKRAPANI, C/O STERING WINTHROP INC
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The invention relates to substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 
salts, to pharmaceutical compositions 
containing the same and to the method of use thereof in the treatment 
or prevention of neurodegenerative disorders or neurotoxic injuries. Fields, U.S. Patent 3,517,073 discloses compounds of 
the formula: 
wherein each of R¹, R², R³ and R⁴ when taken separately, is 
hydrogen, lower alkyl, lower aryl, lower acyloxy, lower alkoxy, nitro, 
halogen, lower acylamino, di(lower alkyl) amino; one group of 
R¹ and R², R² and R³, and R³ and R⁴, preferably R¹ and R², and 
R³ and R⁴, each group when taken together, represents a fused ring 
system containing up to three 6-member carbocyclic and nitrogen-containing 
heterocyclic rings at least one of which is an aromatic 
ring, and having no more than two nuclear nitrogens in any ring, 
which may be unsubstituted or substituted with one or more of the 
substituents defined by R¹, R², R³ and R⁴; each of R⁵ and R⁶, when 
taken separately is hydrogen, lower alkyl or lower aryl; each of 
R⁷ and R8, when taken separately, is hydrogen; R⁷ and R⁸, when taken 
together, represent a fused ring system as defined hereinbefore; 
R⁹, when taken individually, is methylene or lower alkyl, lower aryl, 
lower alkenyl, halogen, or cyano substituted methylene; R¹⁰, when 
taken individually, is a protected carbonyl group; R⁹ and R¹⁰, when 
taken together, represent a fused aromatic carbocyclic or heterocyclic 
ring system, whose valence bonds are from adjacent carbons, 
containing up to three 6-membered carbocyclic and nitrogen-containing  
 
heterocyclic rings having no more than two nitrogens in 
any ring and which may be substituted with one or more of the 
substituents defined by R¹, R², R³ and R⁴. Among the compounds 
specifically disclosed are 12,12-diethoxy-11-methyl-9,10-ethano-9,10-dihydro-4a-azoniaanthracene 
perchlorate and 9,10-(O-benzeno)-9,10-dihydro-5-methyl-4a-azoniaanthracene 
perchlorate. Also 
disclosed are compounds of the formula: 
wherein R¹-R¹⁰ are as defined above and m is an odd integer having a 
value of from 1 to 5, inclusive. Among the compounds specifically 
disclosed are 12,12-diethoxy-11-methyl-9,10-ethano-4a-aza-1,2,3,4,4a,9,9a,10-octahydroanthracene 
perchlorate acid salt, 
9,10-(O-benzeno)-5-methyl-4a-aza-1,2,3,4,4a,9,9a,10-octahydroanthracene 
and 12,12-diethoxy-9,10-ethano-11-bromo-4a-aza-1,2,3,4,4a,9,9a,10-octahydroanthracene. 
The above-described 
compounds are disclosed as being intermediates in the synthesis of 
2-napthol
</DESCRIPTION>
<CLAIMS>
A compound of the formula: 
 

wherein: 
   R¹ is hydrogen, or from one to four, the same or different, 

substituents in any of the 1⁻,2⁻,3⁻ or 4⁻ positions selected from the 
group consisting of lower-alkoxy, lower-alkyl, halogen, hydroxy, 

OC(O) alkyl-CH=CH-alkyl, OC(O) alkyl, 
OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, 

hydroxymethyl, nitro, amino and lower-alkylsulfonylamino or 
R¹ is a fused benzene ring; 

   R² is hydrogen, lower-alkyl, cyano or lower-alkoxycarbonyl; 
   R³ and R⁴ are independently hydrogen, or lower-alkyl; or 

   R³ and R⁴ together form a cycloalkyl ring, or a lower-alkylidene 
group; 

   R⁵ and R⁶ are independently phenyl (or phenyl substituted by 
lower-alkoxy, halogen, lower-alkyl, polyfluorolower-alkyl, lower-alkoxyphenyl-lower-alkyl-N(lower-alkylsulfonyl), 

hydroxy, or 
polychlorolower-alkyl), a 5- or 6-membered monocyclic or 

9- or 10-membered bicyclic aromatic heterocyclic ring system or a 
5- or 6-membered monocyclic nonaromatic heterocyclic ring system 

(or said 5- or 6- membered monocyclic or 9- or 10-membered 
bicyclic aromatic heterocyclic ring system or said 5- or 6- membered 

monocyclic nonaromatic heterocyclic ring system substituted on any 
available carbon atom thereof by hydroxy, lower-alkyl, oxo, nitro, 

halogen, or lower-alkoxy; or on any available nitrogen atom thereof 
by lower-alkyl, phenyl-lower-alkyl (or said phenyl lower-alkyl group 

substituted on the phenyl group by lower-alkoxy, lower-alkyl, or 
halogen), trilower-alkylsilyl, lower-alkylphenylsulfonyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl), 

 
lower-alkoxy, or lower-alkynyl; 

or R⁵ and R⁶ together form a fluorene ring; 
   or R³ and R⁵, and/or R⁴ and R⁶ taken together with the carbon 

atoms to which they are attached form a bicyclic ring system of 
Formula A: 

 
wherein 

   A is phenyl, or a 5- or 6-membered monocyclic aromatic 
heterocyclic ring system and n is an integer from one to three (or said 

A ring substituted on any available carbon atom thereof by lower-alkoxy 
or lower-alkyl); 

   R⁷ is hydrogen, or from one to four, the same or different, 
substituents in any of the 7⁻, 8⁻,9⁻, or 10⁻ positions selected from the 

group consisting of lower-alkyl, lower-alkanoyloxy, halogen, nitro, 
hydroxy, lower-alkoxy, methylenedioxy, polyfluoro-lower-alkyl, 

OCO(CH₂)mC(O)Oalkyl, OC(O)alkyl, C(O)Oalkyl, CO₂₋, carboxy, 
sulfo, SO₃₋, PO₃H, PO₃₋, cyano, polychloro-lower-alkyl, 

OC(O)alkyl-CH=CH-alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, 
alkoxy, OC(O)alkylC(O)Oalkyl, halomethyl, hydroxymethyl, amino 

and lower-alkylsulfonylamino wherein m is an integer from one to 
four and/or R⁷ is a fused pyrazole ring; 

   X⁻ is an anion; and p is zero when R⁷ is a negatively charged 
radical and p is one when R⁷ is other than a negatively charged 

radical; 
or a pharmaceutically acceptable acid-addition salt of basic members 

thereof; or a solvate thereof; or a stereoisomer thereof; with the 
following provisos 


a) at least one of R⁵ and R⁶ when taken individually must be a 
substituted or unsubstituted phenyl group, or a substituted or 

unsubstituted 5- or 6-membered monocyclic or 9- or 10-membered 
bicyclic aromatic heterocyclic ring system or a substituted or 

 
unsubstituted 5- or 6-membered nonaromatic heterocyclic ring 

system; 
b) when R³ and R⁵ or R⁴ and R⁶ together form a bicyclic ring 
system of formula A wherein A is phenyl and n is 1; R¹,R²,R⁴ and 

R⁶ or R¹,R²,R³ and R⁵, respectively are hydrogen and X⁻ is BF₄₋, 
R⁷ is other than hydrogen or 9-methyl; 
c) when R¹,R²,R³ and R⁴ are hydrogen; R⁵ and R⁶ are phenyl, and 
X⁻ is ClO₄₋ or Br⁻; R⁷ is other than hydrogen, 
d) when R¹,R²,R³ and R⁴ are hydrogen; one of R⁵ or R⁶ is phenyl, 
and one of R⁵ or R⁶ is methoxy; and X⁻ is BF₄₋, R⁷ is other than 

hydrogen or 9-methyl; and 
e) when R¹,R²,R³ and R⁴ are hydrogen; R⁵ is 4-morpholinyl and 
R⁶ is phenyl or R⁵ is phenyl and R⁶ is 4-morpholinyl; and 

X⁻ is ClO₄₋, Br⁻ or BF₄₋, R⁷ is other than hydrogen, 9-methyl, or 
7,10-dimethyl. 
A compound according to claim 1 wherein: 
   R¹ is hydrogen, or from one to four, the same or different, 

substituents in any of the 1⁻,2⁻,3⁻ or 4⁻ positions selected from the 
group consisting of lower-alkoxy, lower-alkyl, and halogen; 

   R² is hydrogen, or lower-alkyl; 
   R³ and R⁴ are independently hydrogen, or lower-alkyl; or 

   R³ and R⁴ together form a cycloalkyl ring, or a lower 
alkylidene group; 

   R⁵ and R⁶ are independently phenyl (or phenyl substituted by 
lower-alkoxy, halogen, lower-alkyl, polyfluorolower-alkyl, lower-alkoxyphenyl-lower-alkyl-N(lower-alkylsulfonyl), 

hydroxy, or 
polychlorolower-alkyl), a 5- or 6-membered monocyclic or 

9- or 10-membered bicyclic aromatic heterocyclic ring system or a 
5- or 6-membered monocyclic nonaromatic heterocyclic ring system 

(or said 5- or 6- membered monocyclic or 9- or 10-membered 
bicyclic aromatic heterocyclic ring system or said 5- or 6- membered 

monocyclic nonaromatic heterocyclic ring system substituted on any 
available carbon atom thereof by lower-alkyl, oxo, nitro, halogen, or 

lower-alkoxy; or on any available nitrogen atom thereof by lower-alkyl, 
phenyl-lower-alkyl (or said phenyl lower-alkyl group 

 
substituted on the phenyl group by lower-alkoxy, lower-alkyl, or 

halogen), trilower-alkylsilyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl), 
lower-alkoxy, or lower-alkynyl; or R⁵ and R⁶ together 

form a fluorene ring; 
   or R³ and R⁵, and/or R⁴ and R⁶ taken together with the carbon 

atoms to which they are attached form a bicyclic ring system of 
Formula A: 

 
wherein 

   A is phenyl, or a 5- or 6-membered monocyclic aromatic 

heterocyclic ring system and n is an integer from one to three (or said 
A ring substituted on any available carbon atom thereof by lower-alkoxy, 

or lower-alkyl); 
   R⁷ is hydrogen, or from one to four, the same or different, 

substituents in any of the 7⁻, 8⁻,9⁻, or 10⁻ positions selected from the 
group consisting of lower-alkyl, lower-alkanoyloxy, halogen, nitro, 

hydroxy, lower-alkoxy, methylenedioxy, polyfluorolower-alkyl, 
OCO(CH₂)mC(O)Oalkyl, OC(O)alkyl, C(O)Oalkyl, CO₂₋, carboxy, 

sulfo, SO₃₋, PO₃H, PO₃₋, cyano, and polychlorolower-alkyl, wherein 
m is an integer from one to four; 

   X⁻ is an anion; and p is zero when R⁷ is a negatively charged 
radical and p is one when R⁷ is other than a negatively charged 

radical; 
or a pharmaceutically acceptable acid-addition salt of basic members 

thereof; or a solvate thereof; or a stereoisomer thereof; with the 
following provisos 


a) at least one of R⁵ and R⁶ when taken individually must be a 
substituted or unsubstituted phenyl group, or a substituted or 

unsubstituted 5- or 6-membered monocyclic or 9- or 10-membered 
bicyclic aromatic heterocyclic ring system or a substituted or 

 
unsubstituted 5- or 6-membered nonaromatic heterocyclic ring 

system; 
b) when R³ and R⁵ or R⁴ and R⁶ together form a bicyclic ring 
system of formula A wherein A is phenyl and n is 1; R¹,R²,R⁴ and 

R⁶ or R¹,R²,R³ and R⁵, respectively are hydrogen and X⁻ is BF₄⁻, 
R⁷ is other than hydrogen or 9-methyl; 
c) when R¹,R²,R³ and R⁴ are hydrogen; R⁵ and R⁶ are phenyl, and 
X⁻ is ClO₄₋ or Br⁻; R⁷ is other than hydrogen, 
d) when R¹,R²,R³ and R⁴ are hydrogen; one of R⁵ or R⁶ is phenyl, 
and one of R⁵ or R⁶ is methoxy; and X⁻ is BF₄₋, R⁷ is other than 

hydrogen or 9-methyl; and 
e) when R¹,R²,R³ and R⁴ are hydrogen; R⁵ is 4-morpholinyl and 
R⁶ is phenyl or R⁵ is phenyl and R⁶ is 4-morpholinyl; and 

X⁻ is ClO₄₋, Br⁻ or BF₄₋, R⁷ is other than hydrogen, 9-methyl, or 
7,10-dimethyl. 
A compound according to claim 2 wherein R⁵ and R⁶ are 
independently phenyl (or phenyl substituted by lower-alkoxy, 

halogen, lower-alkyl, polyfluorolower-alkyl, lower-alkoxyphenyl-lower-alkyl-N(lower-alkylsulfonyl), 
hydroxy, or polychlorolower-alkyl), 

a 5- or 6-membered monocyclic or 9- or 10-membered 
bicyclic aromatic heterocyclic ring system (or said 5- or 6-membered 

monocyclic or 9- or 10-membered bicyclic aromatic heterocyclic ring 
system substituted on any available carbon atom thereof by lower-alkyl, 

oxo, or lower-alkoxy; or on any available nitrogen atom thereof 
by lower-alkyl, phenyl-lower-alkyl (or said phenyl-lower-alkyl group 

substituted on the phenyl group by lower-alkoxy, lower-alkyl, or 
halogen), trilower-alkylsilyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl), 

lower-alkoxy, or lower-alkynyl; or R⁵ and R⁶ together 
form a fluorene ring; and R⁷ is hydrogen, or from one to four, the 

same or different, substituents in any of the 7-, 8-, 9- or 10- positions 
selected from the group consisting of lower-alkyl, lower-alkanoyloxy, 

halogen, nitro, hydroxy, lower-alkoxy, methylenedioxy, polyfluorolower-alkyl, 
SO₃₋, and polychlorolower-alkyl. 
A compound according to claim 3 wherein R⁵ and R⁶ are 
independently phenyl (or phenyl substituted by lower-alkoxy, 

halogen, lower-alkyl, polyfluorolower-alkyl, or lower-alkoxyphenyl-lower-alkyl-N(lower-alkylsulfonyl)-), 
a 5- or 6-membered 

monocyclic or 9-membered bicyclic aromatic heterocyclic ring 
system (or said 5- or 6-membered monocyclic or 9-membered 

bicyclic aromatic heterocyclic ring system substituted on any 
available carbon atom thereof by lower-alkyl, oxo, or lower-alkoxy; 

or on any available nitrogen atom thereof by lower-alkoxyphenyl-lower-alkyl, 
trilower-alkylsilyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl), 

lower-alkoxy, or lower-alkynyl; or R⁵ and R⁶ together 
form a fluorene ring; and wherein A is phenyl, or a 5-membered 

monocyclic aromatic heterocyclic ring system and n is an integer 
from one to two (or said A ring substituted on any available carbon 

atom thereof by lower-alkoxy, or lower-alkyl). 
A compound according to claim 4 wherein R¹ is hydrogen, or 
one lower-alkyl substituent in any of the 1⁻,2⁻,3⁻ or 4⁻ positions; and 

R⁷ is hydrogen, or from one to two, the same or different, 
substituents in any of the 7⁻, 8⁻,9⁻, or 10⁻ positions selected from the 

group consisting of halogen, hydroxy, lower-alkoxy SO₃₋ and 
polyfluorolower-alkyl. 
A compound according to claim 5 wherein R⁵ and R⁶ are 
independently phenyl (or phenyl substituted by lower-alkoxy, 

halogen, lower-alkyl, trifluoromethyl, or lower-alkoxyphenyl-lower-alkyl-N(lower-alkylsulfonyl)), 
a 5- or 6-membered monocyclic or 

9-membered bicyclic aromatic heterocyclic ring system selected from 
the group consisting of furanyl, benzofuranyl, pyridinyl, thienyl, 

oxazolyl, thiazolyl, pyrazolyl, triazolyl and pyrrolyl (or said 
5- or 6- membered monocyclic or 9-membered bicyclic aromatic 

heterocyclic ring system substituted on any available carbon atom 
thereof by lower-alkyl, oxo or lower-alkoxy; or any available 

nitrogen atom thereof by lower-alkoxyphenyl-lower-alkyl, trilower-alkylsilyl, 
or trilower-alklsilyl-lower-alkoxy-lower-alkyl), lower-alkoxy, 

or lower-alkynyl; or R⁵ and R⁶ together form a fluorene ring; 
and

 
   A is phenyl, or a 5- membered monocyclic aromatic 

heterocyclic ring system selected from the group consisting of 
furanyl, isoxazolyl and thienyl (or said A ring substituted on any 

available carbon atom thereof by lower-alkoxy, or lower-alkyl). 
A compound according to claim 6 wherein R⁵ and R⁶ are 
independently phenyl (or phenyl substituted by methoxy, bromine, 

chlorine, fluorine, methyl, trifluoromethyl, or 
CH₃O-Ph-CH₂-N(SO₂CH₃)-), a 5- or 6-membered monocyclic or 

9-membered bicyclic aromatic heterocyclic ring system selected 
from the group consisting of 2-furanyl, 3-furanyl, 2-benzofuranyl, 

2⁻,3⁻ and 4⁻pyridinyl, 2-thienyl, 3-thienyl, 4-oxazolyl, 2-thiazolyl, 
5-thiazolyl, 5-pyrazolyl, 5-(1,2,3-triazolyl) and 3-pyrrolyl (or said 

5- or 6- membered monocyclic or 9-membered bicyclic aromatic 
heterocyclic ring system substituted on any available carbon atom 

thereof by methyl, oxo, or methoxy; or any available nitrogen atom 
thereof by methoxyphenylmethyl, triisopropylsilyl, or 

(CH₃)₃Si(CH₂)₂OCH₂), ethoxy or ethynyl; or R⁵ and R⁶ together 
form a fluorene ring; and A is phenyl, or a 5-membered monocyclic 

aromatic heterocyclic ring system selected from the group consisting 
of [2',3']
 furanyl, [4',5'] isoxazolyl and [2',3']
 thienyl (or said A ring 
substituted on any available carbon atom thereof by methoxy, or 

methyl). 
A compound according to claim 7 wherein R¹ is hydrogen or 
1-lower-alkyl; and R⁷ is hydrogen, or from one to two, the same or 

different, substituents in any of the 7⁻,8⁻, 9⁻, or 10⁻ positions 
selected from the group consisting of bromine, fluorine, hydroxy, 

methoxy, isopropoxy, SO₃₋ and trifluoromethyl. 
A compound according to claim 8 wherein R¹ is hydrogen or 
1-methyl; and R² is hydrogen, methyl or butyl; and R³ and R⁴ are 

independently hydrogen, or methyl; or R³ and R⁴ together form a 
cyclopropyl ring, or a methylidene group. 
A compound according to claim 9 selected from the group 
consisting of: 

   6,11-ethano-12,12-diphenyl-6,11-dihydrobenzo[b]quinolizinium 

X⁻; 
   6,11-ethano-6-methyl-12,12-diphenyl-6,11-dihydrobenzo[b]
quinolizinium 
X⁻
; 
   6,11-ethano-12,12-di(3-furanyl)-6,11-dihydrobenzo[b]
quinolizinium 
X⁻; 

   (-)-6,11-ethano-12,12-di(3-furanyl)-6,11-dihydrobenzo[b]quinolizinium 

X⁻; 
   6,11-ethano-6-methyl-12,12-di(2-thienyl)-6,11-dihydrobenzo[b]
quinolizinium 
X⁻; 

   6,11-ethano-12,12-di(2-thienyl)-6,11-dihydrobenzo[b]quinolizinium 

X⁻; 
   6,11-ethano-6-methyl-12,12-di(3-furanyl)-6,11-dihydrobenzo[b]
quinolizinium 
X⁻; 

   6,11-ethano-12,12-di(3-thienyl)-6,11-dihydrobenzo[b]quinolizinium 

X⁻; and 
   6,11-ethano-12,12-di(2-furanyl)-6,11-dihydrobenzo[b]
quinolizinium 
X⁻. 
A compound according to claim 10 selected from the group 
consisting of: 

   6,11-ethano-12,12-diphenyl-6,11-dihydrobenzo[b]quinolizinium 

chloride; 
   6,11-ethano-6-methyl-12,12-diphenyl-6,11-dihydrobenzo[b]
quinolizinium 
chloride; 

   6,11-ethano-12,12-di(3-furanyl)-6,11-dihydrobenzo[b]quinolizinium 

chloride; 
   (-)-6,11-ethano-12,12-di(3-furanyl)-6,11-dihydrobenzo[b]
quinolizinium 
chloride; 

   6,11-ethano-6-methyl-12,12-di(2-thienyl)-6,11-dihydrobenzo[b]quinolizinium 

chloride; 
   6,11-ethano-12,12-di(2-thienyl)-6,11-dihydrobenzo[b]
quinolizinium 
chloride;

 
   6,11-ethano-6-methyl-12,12-di(3-furanyl)-6,11-dihydrobenzo[b]
quinolizinium 
chloride; 

   6,11-ethano-12,12-di(3-thienyl)-6,11-dihydrobenzo[b]quinolizinium 

chloride; and 
   6,11-ethano-12,12-di(2-furanyl)-6,11-dihydrobenzo[b]
quinolizinium 
chloride. 
(-)-6,11-ethano-12,12-di(3-furanyl)-6,11-dihydrobenzo[b]quinolizinium 

chloride according to claim 11. 
A compound according to claim 9 selected from the group 
consisting of: 

   6,11-ethano-12,12-di(3-furanyl)-10-hydroxy-6,11-dihydrobenzo[b] 

quinolizinium chloride; 
   6,11-ethano-12,12-di(3-pyrrolyl)-6,11-dihydrobenzo[b]
quinolizinium 
chloride; 

   6,11-ethano-12,12-di-(3-furanyl)-9-hydroxy-6,11-dihydrobenzo[b] 

quinolizinium chloride; and 
   6,11-ethano-12,12-di(3-furanyl)-9-fluoro-6,11-dihydrobenzo[b]
quinolizinium 
perchlorate. 
A compound according to claim 2 wherein R⁵ and R⁶ are 
independently phenyl substituted by hydroxy or a 5- or 6-membered 

monocyclic aromatic heterocyclic ring system selected from the 
group consisting of pyrazolyl, triazolyl, pyridinyl, furanyl, imidazolyl 

and pyrrolyl (or said 5- or 6-membered monocyclic aromatic 
heterocyclic ring system substituted on any available carbon atom 

thereof by lower-alkoxy; or any available nitrogen atom thereof by 
lower-alkyl, lower-alkoxyphenyllower-alkyl, or trilower-alkylsilyl); 

R¹ is hydrogen or one lower-alkoxy or halogen substituent in any of 
the 1-, 2-, 3- or 4-positions; and R⁷ is hydrogen, or from one to two, 

the same or different, substituents in any of the 
7-,8-, 9-, or 10- positions selected from the group consisting of 

OC(O)alkyl, OCO(CH₂)mC(O)Oalkyl, hydroxy, lower-alkoxy, 
methylenedioxy, halogen and nitro. 
A compound according to claim 14 wherein R⁵ and R⁶ are 
independently phenyl substituted by hydroxy or a 5- or 6- membered 

monocyclic aromatic heterocyclic ring system selected from the 
group consisting 3-, 4- and 5-pyrazolyl, 5-(1,2,4-triazolyl), 

3-pyridinyl, 3-furanyl, 2-imidazolyl and 3-pyrrolyl (or said 
5- or 6-membered monocyclic aromatic heterocyclic ring system 

substituted on any available carbon atoms thereof by methoxy, or on 
any available nitrogen atom thereof by methyl, methoxyphenylmethyl, 

or triisopropylsilyl); R¹ is hydrogen, 1-halogen, or 1-lower-alkoxy; 
and R⁷ is hydrogen, or from one to two, the same or 

different, substitutents in any of the 7-, 8-, 9- or 10- positions selected 
from the group consisting of OC(O)(CH₂)₆CH₃, 

OCO(CH₂)₂C(O)OCH₂CH₃, OC(O)CH₃, OC(O)t-Bu, hydroxy, 
methoxy, methylenedioxy, chloro, fluoro and nitro. 
A compound according to claim 15 wherein R¹ is hydrogen, 
1-fluoro, or 1-methoxy; R² is hydrogen, or methyl; and R³ and R⁴ 

are independently hydrogen or methyl; or R³ and R⁴ together form a 
methylidene group. 
6,11-Ethano-12,12-di(3-pyrazolyl)-9-hydroxy-6,11-dihydrobenzo[b] 

quinoliziniuim chloride according to claim 16. 
A compound according to claim 1 wherein R¹ is from one to 
four, the same or different, substituents in any of the 

1-, 2-, 3- or 4- positions selected from the group consisting of 
hydroxy, OC(O)alkyl-CH=CH-alkyl, OC(O) alkyl, 

OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, 
hydroxymethyl, nitro, amino and lower-alkylsulfonylamino; or 

R¹ is a fused benzene ring. 
A compound according to claim 18 wherein: 
   R¹ is one substituent in any of the 1-, 2-, 3-, or 4- positions 

selected from the group consisting of hydroxy, and OC(O)alkyl; or 
R¹ is a fused benzene ring; 

   R², R³, R⁴ and R⁷ are hydrogen; and 
   R⁵ and R⁶ are independently a 5- or 6- membered monocyclic 

aromatic heterocyclic ring system selected from the group consisting 
of furanyl, pyridinyl, thienyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, 

pyrrolyl and imidazolyl. 
A compound according to claim 19 wherein R¹ is 1-hydroxy, 
1-OC(O)CH₃ or a fused benzene ring; and R⁵ and R⁶ are furanyl. 
A compound according to claim 1 wherein R² is cyano or 
lower-alkoxycarbonyl. 
A compound according to claim 21 wherein R¹, R³, R⁴ and 
R⁷ are hydrogen; and R⁵ and R⁶ are independently selected from the 

group consisting of furanyl, pyridinyl, thienyl, oxazolyl, thiazolyl, 
pyrazolyl, triazolyl, pyrrolyl and imidazolyl. 
A compound according to claim 22 wherein R⁵ and R⁶ are 
furanyl. 
A compound according to claim 1 wherein R⁷ is from one to 
four, the same or different, substituents in any of the 

7-, 8-, 9- or 10- positions selected from the group consisting of 
OC(O) alkyl-CH=CH-alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, 

alkoxy, OC(O)alkylC(O)Oalkyl, halomethyl, hydroxymethyl, amino 
and lower-alkylsulfonylamino and/or R⁷ is a fused pyrazole ring. 
A compound according to claim 24 wherein R¹, R², R³ and 
R⁴ are hydrogen; and R⁵ and R⁶ are independently a 

5- or 6- membered monocyclic aromatic heterocyclic ring system 
selected from the group consisting of furanyl, pyridinyl, thienyl, 

oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyrrolyl and imidazolyl. 
A compound according to claim 25 wherein R⁵ and R⁶ are 
furanyl and R⁷ is one substituent selected from the group consisting 

of OC(O)(CH₂)₇HC=CH-(CH₂)₇CH₃, 
OC(O)-CH=CH-C(O)OCH₂CH₃, O(CH₂)₇CH₃, 

OC(O)C(CH₃)₂CH₂C(O)OCH₂CH₃, chloromethyl, hydroxymethyl, 
and OC(O)C(CH₃)₂CH₂C(O)O(CH₂)₇CH₃; and/or R⁷ is a fused 

pyrazole ring. 
A pharmaceutical composition which comprises a compound 
of Formula I' 

 
wherein: 

   R¹ is hydrogen, or from one to four, the same or different, 
substituents in any of the 1⁻,2⁻,3⁻ or 4⁻ positions selected from the 

group consisting of lower-alkoxy, lower-alkyl, halogen, hydroxy, 
OC(O) alkyl-CH=CH-alkyl, OC(O) alkyl, 

OC(O)-lower-alkenyl-C(O)Oalkyl, alkoxy, OC(O)alkylC(O)Oalkyl, 
hydroxymethyl, nitro, amino and lower-alkylsulfonylamino or 

R¹ is a fused benzene ring; 
   R² is hydrogen, lower-alkyl, cyano or lower-alkoxycarbonyl; 

   R³ and R⁴ are independently hydrogen, or lower-alkyl; or 
R³ and R⁴ together form a cycloalkyl ring, or a lower-alkylidene 

group; 

   R⁵ and R⁶ are independently phenyl (or phenyl substituted by 
lower-alkoxy, halogen lower-alkyl, polyfluorolower-alkyl, lower-alkoxyphenyl-lower-alkyl-N(lower-alkylsulfonyl), 

hydroxy, or 
polychlorolower-alkyl), a 5- or 6-membered monocyclic or 

9- or 10-membered bicyclic aromatic heterocyclic ring system or a 
5- or 6-membered monocyclic nonaromatic heterocyclic ring system 

(or said 5- or 6- membered monocyclic or 9- or 10-membered 
bicyclic aromatic heterocyclic ring system or said 5- or 6- membered 

 
monocyclic nonaromatic heterocyclic ring system substituted on any 

available carbon atom thereof by hydroxy, lower-alkyl, oxo, nitro, 
halogen, or lower-alkoxy; or on any available nitrogen atom thereof 

by lower-alkyl, phenyl-lower-alkyl (or said phenyl-lower-alkyl group 
substituted on the phenyl group by lower-alkoxy, lower-alkyl, or 

halogen), trilower-alkysilyl, lower-alkylphenylsulfonyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl), 
lower-alkoxy, or lower-alkynyl; 

or R⁵ and R⁶ together form a fluorene ring; 
   or R³ and R⁵, and/or R⁴ and R⁶ taken together with the 

carbon atoms to which they are attached form a bicyclic ring system 
of Formula A: 

 
wherein 

   A is phenyl, or a 5- or 6-membered monocyclic aromatic 
heterocyclic ring system and n is an integer from one to three (or said 

A ring substituted on any available carbon atom thereof by lower-alkoxy, 
or lower-alkyl); 

   R⁷ is hydrogen, or from one to four, the same or different, 
substituents in any of the 7⁻, 8⁻, 9⁻, or 10⁻ positions selected from the 

group consisting of lower-alkyl, lower-alkanoyloxy, halogen, nitro, 
hydroxy, lower-alkoxy, methylenedioxy, polyfluorolower-alkyl, 

OCO(CH₂)mC(O)Oalkyl, OC(O)alkyl, C(O)Oalkyl, CO₂₋, carboxy, 
sulfo, SO₃₋, PO₃H, PO₃₋, cyano, polychlorolower-alkyl, 

OC(O)alkyl-CH=CH-alkyl, OC(O)-lower-alkenyl-C(O)Oalkyl, 
alkoxy, OC(O)alkylC(O)Oalkyl, halomethyl, hydroxymethyl, amino 

and lower-alkylsulfonylamino; wherein m is a integer from one to 
four; and/or R⁷ is a fused pyrazole ring; 

   X⁻ is an anion; and p is zero when R⁷ is a negatively charged 
radical and p is one when R⁷ is other than a negatively charged 

radical;
 

or a pharmaceutically acceptable acid-addition salt of basic members 
thereof; or a solvate thereof; or a stereoisomer thereof; together with 

a pharmaceutically acceptable carrier, adjuvant, diluent or vehicle, 
with the proviso that at least one of R⁵ and R⁶ when taken 

individually must be a substituted or unsubstituted phenyl group, or a 
substituted or unsubstituted 5- or 6-membered monocyclic or 9- or 

10-membered bicyclic aromatic heterocyclic ring system or a 
substituted or unsubstituted 5- or 6-membered monocyclic 

nonaromatic heterocyclic ring system. 
A pharmaceutical composition according to claim 27 wherein: 
   R¹ is hydrogen, or from one to four, the same or different, 

substituents in any of the 1⁻,2⁻,3⁻ or 4⁻ positions selected from the 
group consisting of lower-alkoxy, lower-alkyl, and halogen; 

   R² is hydrogen, or lower-alkyl; 
   R³ and R⁴ are independently hydrogen, or lower-alkyl; or 

   R³ and R⁴ together form a cycloalkyl ring, or a lower 
alkylidene group; 

   R⁵ and R⁶ are independently phenyl (or phenyl substituted by 
lower-alkoxy, halogen, lower-alkyl, polyfluorolower-alkyl, lower-alkoxyphenyl-lower-alkyl-N(lower-alkylsulfonyl), 

hydroxy, or 
polychlorolower-alkyl), a 5- or 6-membered monocyclic or 

9- or 10-membered bicyclic aromatic heterocyclic ring system or a 
5- or 6-membered monocyclic nonaromatic heterocyclic ring system 

(or said 5- or 6- membered monocyclic or 9- or 10-membered 
bicyclic aromatic heterocyclic ring system or said 5- or 6- membered 

monocyclic nonaromatic heterocyclic ring system substituted on any 
available carbon atom thereof by lower-alkyl, oxo, nitro, halogen, or 

lower-alkoxy; or on any available nitrogen atom thereof by lower-alkyl, 
phenyl-lower-alkyl (or said phenyl lower-alkyl group 

substituted on the phenyl group by lower-alkoxy, lower-alkyl, or 
halogen), trilower-alkylsilyl, or trilower-alkylsilyl-lower-alkoxy-lower-alkyl), 

lower-alkoxy, or lower-alkynyl; or R⁵ and R⁶ together 
form a fluorene ring;

 
   or R³ and R⁵, and/or R⁴ and R⁶ taken together with the carbon 

atoms to which they are attached form a bicyclic ring system of 
Formula A: 

 
wherein 

   A is phenyl, or a 5- or 6-membered monocyclic aromatic 
heterocyclic ring system and n is an integer from one to three (or said 

A ring substituted on any available carbon atom thereof by lower-alkoxy, 
or lower-alkyl); 

   R⁷ is hydrogen, or from one to four, the same or different, 
substituents in any of the 7⁻, 8⁻,9⁻, or 10⁻ positions selected from the 

group consisting of lower-alkyl, lower-alkanoyloxy, halogen, nitro, 
hydroxy, lower-alkoxy, methylenedioxy, polyfluorolower-alkyl, 

OCO(CH₂)mC(O)Oalkyl, OC(O)alkyl, C(O)Oalkyl, CO₂₋, carboxy, 
sulfo, SO₃₋, PO₃H, PO₃₋, cyano, and polychlorolower-alkyl, wherein 

m is an integer from one to four; 
   X⁻ is an anion; and p is zero when R⁷ is a negatively charged 

radical and p is one when R⁷ is other than a negatively charged 
radical; 

or a pharmaceutically acceptable acid-addition salt of basic members 
thereof; or a solvate thereof; or a stereoisomer thereof; together with 

a pharmaceutically acceptable carrier, adjuvant, diluent or vehicle, 
with the proviso that at least one of R⁵ and R⁶ when taken 

individually must be a substituted or unsubstituted phenyl group, or a 
substituted or unsubstituted 5- or 6-membered monocyclic or 

9- or 10-membered bicyclic aromatic heterocyclic ring system or a 
substituted or unsubstituted 5- or 6-membered monocyclic 

nonaromatic heterocyclic ring system. 
A pharmaceutical composition comprising a compound 
according to any one of claims 3 to 26 together with a 

pharmaceutically acceptable carrier, adjuvant, diluent or vehicle. 
The use of a compound of Formula I' as defined in 
claim 27 for the preparation of a medicament for the treatment or 

prevention of neurodegenerative disorders or neurotoxic injuries in a 
patient in need of such treatment. 
The use of a compound of Formula I' as defined in 
claim 28 for the preparation of a medicament for the treatment or 

prevention of neurodegenerative disorders or neurotoxic injuries in a 
patient in need of such treatment. 
The use of a compound of Formula I' as defined in claim 29 
for the preparation of a medicament for the treatment or prevention of 

neurodegenerative disorders or neurotoxic injuries in a patient in need 
of such treatment. 
The use according to any one of claims 30 to 32 wherein said 
neurotoxic injuries are associated with ischemic, hypoxic, or 

hypoglycemic conditions. 
The use according to claim 33 wherein said ischemic, hypoxic, 
or hypoglycemic conditions are associated with stroke. 
</CLAIMS>
</TEXT>
</DOC>
